Ohr Pharmaceutical Inc (OHRP) 9.26 $OHRP Seeking Alpha's

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 9:12 PM

Ohr Pharmaceutical Inc (OHRP) 9.26 $OHRP

Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 317.06 (+2.65), PCYC: 257.85 (-0.21), ITEK: 5.75 (-0.19), REDX: (), PTX: 10.40 (-0.34), CLDX: 30.38 (-1.40), ILMN: 196.02 (-3.79), IDGX: (), ACAD: 34.45 (-0.54), TRGT: 2.66 (-0.07), CLLS: (), EXAC: 25.30 (+0.52), ABBV: 60.40 (-0.79), CRMD: 7.75 (-0.18), AGMX: (), ZGNX: 1.38 (+0.02), VVUS: 2.97 (-0.02), SPPI: 6.17 (-0.24), GSK: 48.81 (+0.60), OREX: 7.19 (-0.41), SQNM: 3.91 (-0.03), IRWD: 16.59 (+0.18), GILD: 102.29 (+0.85), MRK: 58.58 (+0.37), OHRP: 9.26 (-0.09), TEVA: 62.10 (+0.55)

Ohr Pharmaceutical And Squalamine: Questions Abound
Pharma Investor - at Seeking Alpha - Wed Mar 11, 8:36AM CDT

OHRP: 9.26 (-0.09)

Ohr Pharmaceutical (OHRP) Jumps: Stock Moves 27.2% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 7:51AM CST
Ohr Pharmaceutical, Inc. (OHRP) was a big mover last session, as the company saw its shares rise over 27% on the day.
LCI: 68.57 (-0.32), OHRP: 9.26 (-0.09)

Ohr Pharmaceutical to Present at the 35th Annual Cowen & Company Health Care Conference
GlobeNewswire - Tue Mar 03, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 35 Annual Cowen & Company Health Care Conference.
OHRP: 9.26 (-0.09)

Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 34.25 (+0.10), OPHT: 51.40 (-1.60), GSK: 48.81 (+0.60), PFNX: 14.73 (+0.06), LPTN: 3.46 (-0.21), AGN: 240.22 (+2.88), AAVL: 44.61 (+0.36), OHRP: 9.26 (-0.09), NVS: 101.68 (+1.81)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 11:49AM CST

DRAM: 2.30 (+0.09), BIOC: 2.45 (-0.12), GTI: 4.00 (+0.08), TTI: 5.91 (+0.27), NXPI: 108.03 (+2.71), LL: 28.51 (-0.84), KOS: 8.24 (-0.11), CORE: 65.24 (+0.18), OMER: 24.94 (-0.43), DQ: 27.60 (+2.47), CYCC: 0.98 (+0.02), BORN: 1.09 (-0.06), AVEO: 1.35 (-0.16), SCMP: 17.89 (-0.67), BIOS: 4.49 (-0.06), OHRP: 9.26 (-0.09), MITL: 10.74 (+0.29), TCON: 14.20 (-1.40), PCRX: 97.64 (-0.08), NAVI: 20.70 (+0.03)

Ohr Pharma up on wet-AMD study results
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:17AM CST

OHRP: 9.26 (-0.09)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 8:15AM CST

CVM: 1.11 (unch), NBG: 1.34 (+0.14), NXPI: 108.03 (+2.71), LL: 28.51 (-0.84), LPI: 11.98 (+0.21), WBAI: 11.06 (+1.08), ANFI: 9.66 (-0.15), SYN: 2.59 (+0.06), GDP: 3.12 (+0.09), CYCC: 0.98 (+0.02), EGO: 5.09 (+0.21), CYTX: 1.19 (-0.03), TCPI: 2.35 (-0.01), OHRP: 9.26 (-0.09), ATHX: 3.20 (+0.03), ARCP: 10.09 (+0.23), FSL: 43.39 (+0.82), PCRX: 97.64 (-0.08), NAVI: 20.70 (+0.03), SMRT: 12.59 (+0.19)

Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting
GlobeNewswire - Mon Mar 02, 6:30AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity previously reported from this study. The data were presented by Jason S. Slakter, MD, Chief Medical Officer at Ohr and Clinical Professor of Ophthalmology, NYU School of Medicine.
OHRP: 9.26 (-0.09)

Short Interest Declines 21% For OHRP
MarketNewsVideo.com - Thu Feb 26, 3:01PM CST
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 616,014 share decrease in total short interest for Ohr Pharmaceutical, Inc. , to 2,307,932, a decrease of 21.07% since 01/30/2015.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical concludes public offering at USD6.75 per share
M2 - Thu Feb 12, 5:16AM CST
Ophthalmology company Ohr Pharmaceutical (NasdaqCM:OHRP) revealed on Wednesday the completion of its public offering of common stock at USD6.75 per share.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 11, 11:54AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it has closed its previously announced public offering of common stock. The Company sold 4,259,259 common shares in the offering, including 555,555 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $6.75 per share, and the gross proceeds to the Company from the sale of the shares were approximately $28.8 million. The transaction was led by new investors Deerfield Management Company, L.P., and Broadfin Capital LLC, and included participation from new and existing investors.
OHRP: 9.26 (-0.09)

OHR reports 1Q loss
Automated Insights - Mon Feb 09, 4:16PM CST
SALT LAKE CITY, Utah (AP) _ Ohr Pharmaceutical Inc. (OHRP) on Monday reported a loss of $4.6 million in its fiscal first quarter.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical beats by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:56PM CST

OHRP: 9.26 (-0.09)

Ohr Pharmaceutical Reports Fiscal First Quarter 2015 Financial and Business Results
GlobeNewswire - Mon Feb 09, 3:01PM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its first fiscal quarter ended December 31, 2014.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical (OHRP) in Focus: Stock Falls 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:30AM CST
Ohr Pharmaceutical saw a big move last session, as the company’s shares fell by over 8% on the day.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York
GlobeNewswire - Mon Feb 09, 7:06AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 17 Annual BIO CEO & Investor Conference, and the Leerink Global Healthcare Conference.
OHRP: 9.26 (-0.09)

Ohr Pharmaceutical prices public offering at USD6.75 per share
M2 - Mon Feb 09, 6:09AM CST
Ophthalmology company Ohr Pharmaceutical (NasdaqCM:OHRP) stated on Friday that it has priced a public offering of 3,703,704m shares of its common stock.
OHRP: 9.26 (-0.09)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST

HRS: 72.75 (+0.57), GPRO: 40.40 (+0.87), NLST: 1.23 (-0.05), TROV: 7.04 (-0.35), AU: 9.84 (+0.44), NMM: 9.75 (-1.13), EOX: 0.86 (+0.01), NBG: 1.34 (+0.14), ONTY: 1.72 (-0.05), ATVI: 23.42 (+0.27), PBR: 5.59 (+0.33), XLS: 23.80 (+0.06), MHR: 2.39 (+0.07), CIG: 3.92 (+0.30), PWE: 1.51 (unch), LNKD: 264.25 (+3.67), GDP: 3.12 (+0.09), SFY: 2.12 (-0.07), P: 16.34 (+0.11), TPX: 59.14 (+1.46), EXPE: 95.91 (+1.23), OHRP: 9.26 (-0.09), TWTR: 48.44 (+0.51), YELP: 44.94 (-0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

China's 15th Plan: Key Moves in the Capital Markets

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Superteam Wheels Rides Into Spain with RACEIT Deal

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Zinzino Eyes European Market With New Botanical Line

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

HCLTech Partners with Rapidus on Semiconductor Future

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

ASICS and University of Michigan Launch Innovation Lab

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...